« Back
Home /
dubermatinib-tp-0903

dubermatinib-tp-0903

Manufacturer	InvivoChem LLC
Category	Reagents & Chemicals Molecules
Type	Biochemicals
Specific against	other
Amount	250mg
Item no.	V0639-250mg
CASRN	1341200-45-0
eClass 6.1	32160405
eClass 9.0	32160490
Available
Description	InvivoChem Cat #:V0639CAS #:1341200-45-0Purity >=98% Description: Dubermatinib (formerly also known as TP-0903; TP-0903) is a novel, selective and orally bioavailable inhibitor of the AXL receptor tyrosine kinase with potential antineoplastic activity. It inhibits AXL with an IC50 of 27 nM. In recent years, the receptor tyrosine kinase AXL has emerged as an potential oncologic target owing to its over expression in different types of cancers combined with its capability to facilitate tumor growth and metastasis. Description: References: ACS Med Chem Lett. 2011 Dec 8; 2(12):907-912; Clin Cancer Res. 2015 May 1; 21(9):2115-26. References:
Molecular Weight (MW)	516.06
Formula	C24H30ClN7O2S
CAS No.	1341200-45-0
Storage	-20C for 3 years in powder form
	-80C for 2 years in solvent
Solubility (In vitro)	DMSO: 3 mg/mL (5.8 mM)
	Water: < 1 mg/mL
	Ethanol: 1 mg/mL (1.9 mM)
Solubility (In vivo)	0.5% CMC Na+1% Tween 80: 30mg/mL
Synonyms	Dubermatinib; TP-0903; TP0903; TP 0903
Chemical Name	2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N, N-dimethylbenzenesulfonamide
SMILES Code	O=S(C1=CC=CC=C1NC2=NC(NC3=CC=C(CN4CCN(C)CC4)C=C3)=NC=C2Cl)(N(C)C)=O

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 250mg

available

Delivery expected until 7/4/2024